Back to results

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

Primary Purpose

Chemotherapy-induced Nausea and Vomiting

Status

Unknown status

Phase

Not Applicable

Locations

China

Study Type

Interventional

Intervention

Thalidomide

Dexamethasone

5-HT3 antagonists

About this trial

This is an interventional prevention trial for Chemotherapy-induced Nausea and Vomiting focused on measuring Thalidomide, Chemotherapy-induced Nausea and Vomiting, cisplatin

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

18y ≤Age≤70y
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Histologically confirmed solid neoplasm
No prior chemotherapy
Laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/ L, neutrophil count ≥1.5×109/L, platelet count ≥85×109/L, creatinine clearance rate (CCr) ≥60ml/min, total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L
Life expectancy of at least 12 weeks
Signed informed consent
For women with child bearing potential, a negative serum or urine pregnancy test result should be obtained before enrollment;the patients and their couples should receive contraception for at least 3 years after their last dosage of thalidomide.
Cancer patients scheduled to receive chemotherapy containing a 50 mg/m2 or higher dose of cisplatin for 4-6 cycles

Exclusion Criteria:

Diabetic patients
Pregnant or lactated women
Patient with history of severe thrombosis
Concomitant radiotherapy
Known hypersensitivity yo thalidomide, palonosetron, or dexamethasone.
Concurrent administration of any other drug which affect antiemetic effect evaluation such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs
Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP )regiment or taxanes-based regiment
Existing emesis within 24 hours before chemotherapy administration
Symptomatic brain metastasis or suspected clinical brain metastasis
Serious uncontrolled systemic illness or medical condition: congestive heart failure, unstable angina, history of documented myocardial infarction within 6 months, uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious neurological or mental abnormalities including mental disorder, epileptic dementia, which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer or other contraindication for corticosteroid therapy.
Inability to take or absorb oral medicine
Concurrent administration of any other investigational drug, or have been enrolled in other clinical trial with investigational drug treatment within the 30 days of start of study treatment
Unsuitable for the study or other chemotherapy determined by investigator

Sites / Locations

cancer hospital of Haerbin Medical University
Siping City Cancer Hospital
Anshan Hospital of First Hospital of China Medical University
Anshan Tumor Hospital
Central hospital of Dalian
Second Affiliated Hospital of Dalian Medical University
The Fifth Hospital of Dalian City
The First Affiliated Hospital of Dalian Medical University
Zhuanghe Central Hospital
Fushun Central HospitalRecruiting
General Hospital of Mining Bureau
Jinzhou Central Hospital
The First Hospital of Liaoning Medical University
Chinese Medicine Hospital of Liaoyang county
Liaoyang Central Hospital
Petrochemical General Hospital of Liaoyang city
Panjin central Hospital
Chest Hospital of Shenyang City
Shengjing Hospital of China Medical University
General Hospital of Shenyang Military Region
Liaoning Tumor Hospital & Institute
The First Hospital of China Medical UniversityRecruiting
the People'S Hospital
Tieling city Central Hospital
Central Hospital of Anshan City
Benxi Central Hospital
Chaoyang Central Hospital
Zhongshan Hospital
Liaohe Oilfield General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Control group

Thalidomide group

Arm Description

Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.

Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.

Outcomes

Primary Outcome Measures

No nausea （self report sclae VAS=0）rate in delayed phase (Days2-7) in the first cycle chemotherapy

The rate of no nausea on Day 2-7 in the first chemotherapy cycle (each cycle is 21 days). The no nausea is defined as score zero with a self-report measure scale,the visual analogue (VAS) scale (0,no symptom, 10, most severely).

Secondary Outcome Measures

No nausea rates （VAS=0）for delayed phases (Days2-7) during 2nd to 4th or 6th chemotherapy cycle,respectively.

The rates of no nausea on day 2-7 in 2nd-4th or 6th cycle (each cycle is 21 days). The no nausea is defined as score zero with a self-report measure scale,the visual analogue (VAS) scale (0,no symptom, 10, most severely).

The complete response rates of vomiting (no emetic episode and no rescue) in acute (Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.

The rates of no emetic episode and no rescue in acute(Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.(each cycle is 21 days). An emetic episode is defined as one occurrence of vomiting or a sequence of occurrences in close succession not relieved by a rest period of at least 1 min; any number of episodes of retching in a 5-minute period; or an episode of retching of , 5 minutes combined with vomiting not relieved in a 1-minute period.

The rate of no anorexia (VAS=0) and score of anorexia (assessed by VAS) in Day1-7 during 1st-4th or 6th cycle chemotherapy

The rate of no anorexia (VAS=0) and score of anorexia assessed by VAS in multi-cycle chemotherapy. Anorexia score is evaluated with VAS (0,no symptom, 10, most severely)

The score of fatigue by VAS in day1-7 in1st to 4th or 6th chemotherapy cycle,respectively.

The score of fatigue by self-report scale VAS in day1-7 in1st to 4th or 6th chemotherapy. fatigue is evaluated with self-report scale VAS (0,no symptom, 10, most severely）

The score of sedation(by self-report VAS) in day 1-7 in each cycle

The score of sedation(by self-report VAS) in day 1-7 in each cycle, respectively.Sedation is evaluated with self-report VAS (0,no symptom, 10, most severely）

Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in multi-cycle chemotherapy

Number of participants with Treatment-Related Adverse Events as assessed by CTCAE v4.0, in 4-6 cycles (each cycle is 21 days).

The quality of life scores (evaluated with Functional Living Index-Emesis (FLIE) questionnaire) of patients when receiving multi-cycle chemotherapy

The change of quality of life scores from baseline of patients (before chemotherapy) to D8 after chemotherapy in each cycle (each cycle is 21 days). The quality of life are evaluated with Functional Living Index-Emesis (FLIE) questionnaire.

Full Information

NCT ID

NCT03601871

First Posted

May 30, 2018

Last Updated

July 25, 2018

Sponsor

Yunpeng Liu

1. Study Identification

Unique Protocol Identification Number

NCT03601871

Brief Title

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

Official Title

The Efficacy and Safety of Thalidomide in Preventing Multi-cycle, Cisplatin-containing CINV: a Pragmatic Randomized Open-label Clinical Trial

Study Type

Interventional

2. Study Status

Record Verification Date

July 2018

Overall Recruitment Status

Unknown status

Study Start Date

July 12, 2018 (Actual)

Primary Completion Date

June 30, 2020 (Anticipated)

Study Completion Date

December 30, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Yunpeng Liu

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

5. Study Description

Brief Summary

Detailed Description

This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle cisplatin-containing highly emetogenic chemotherapy (HEC) . A total of 880 patients are planned to be enrolled into the study. Chemotherapy-naïve patients treated with multi-cycle cisplatin-containing chemotherapy will be randomized into two groups(thalidomide group and control group), and be treated with Thalidomide+5-hydroxytryptamine receptor(5-HT3) antagonist +Dexamethasone (Thalidomide group) or 5-HT3 antagonist + Dexamethasone(control group), respectively. The primary end point is no nausea rate in delayed phase of the first cycle chemotherapy, and the secondary end points include the complete response rate of vomiting in acute,delayed and overall period; no nausea rate in acute and overall phase; anorexia score, fatigue score and sedation score assessed by VAS ; safety and quality of life (QOL) during multi-cycle chemotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Chemotherapy-induced Nausea and Vomiting

Keywords

Thalidomide, Chemotherapy-induced Nausea and Vomiting, cisplatin

7. Study Design

Primary Purpose

Prevention

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

880 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Control group

Arm Type

Active Comparator

Arm Description

Arm Title

Thalidomide group

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Thalidomide

Intervention Description

Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .

Intervention Type

Drug

Intervention Name(s)

Dexamethasone

Intervention Description

Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4

Intervention Type

Drug

Intervention Name(s)

5-HT3 antagonists

Other Intervention Name(s)

Palonosetron, or 1st-generation 5-HT3 antagonists

Intervention Description

Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3

Primary Outcome Measure Information:

Title

No nausea （self report sclae VAS=0）rate in delayed phase (Days2-7) in the first cycle chemotherapy

Description

Time Frame

Day 2-7 in the first chemotherapy cycle(each cycle is 21 days)

Secondary Outcome Measure Information:

Title

No nausea rates （VAS=0）for delayed phases (Days2-7) during 2nd to 4th or 6th chemotherapy cycle,respectively.

Description

Time Frame

Day 2-7 in each chemotherapy cycle (each cycle is 21 days)

Title

The complete response rates of vomiting (no emetic episode and no rescue) in acute (Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.

Description

Time Frame

Day 1-7 in 4-6 cycles(each cycle is 21 days)

Title

The rate of no anorexia (VAS=0) and score of anorexia (assessed by VAS) in Day1-7 during 1st-4th or 6th cycle chemotherapy

Description

The rate of no anorexia (VAS=0) and score of anorexia assessed by VAS in multi-cycle chemotherapy. Anorexia score is evaluated with VAS (0,no symptom, 10, most severely)

Time Frame

Day 1-7 in each cycle(each cycle is 21 days)

Title

The score of fatigue by VAS in day1-7 in1st to 4th or 6th chemotherapy cycle,respectively.

Description

The score of fatigue by self-report scale VAS in day1-7 in1st to 4th or 6th chemotherapy. fatigue is evaluated with self-report scale VAS (0,no symptom, 10, most severely）

Time Frame

Day 1-7 in each cycle(each cycle is 21 days)

Title

The score of sedation(by self-report VAS) in day 1-7 in each cycle

Description

The score of sedation(by self-report VAS) in day 1-7 in each cycle, respectively.Sedation is evaluated with self-report VAS (0,no symptom, 10, most severely）

Time Frame

Day 1-7 in each cycle(each cycle is 21 days)

Title

Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in multi-cycle chemotherapy

Description

Number of participants with Treatment-Related Adverse Events as assessed by CTCAE v4.0, in 4-6 cycles (each cycle is 21 days).

Time Frame

Day 1-21 in each cycle(each cycle is 21 days) during 4-6 chemotherapy cycles (each cycle is 21 days)

Title

The quality of life scores (evaluated with Functional Living Index-Emesis (FLIE) questionnaire) of patients when receiving multi-cycle chemotherapy

Description

Time Frame

Day 1-8 in each cycle(each cycle is 21 days) during 4-6 chemotherapy cycles.

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: 18y ≤Age≤70y Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 Histologically confirmed solid neoplasm No prior chemotherapy Laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/ L, neutrophil count ≥1.5×109/L, platelet count ≥85×109/L, creatinine clearance rate (CCr) ≥60ml/min, total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L Life expectancy of at least 12 weeks Signed informed consent For women with child bearing potential, a negative serum or urine pregnancy test result should be obtained before enrollment;the patients and their couples should receive contraception for at least 3 years after their last dosage of thalidomide. Cancer patients scheduled to receive chemotherapy containing a 50 mg/m2 or higher dose of cisplatin for 4-6 cycles Exclusion Criteria: Diabetic patients Pregnant or lactated women Patient with history of severe thrombosis Concomitant radiotherapy Known hypersensitivity yo thalidomide, palonosetron, or dexamethasone. Concurrent administration of any other drug which affect antiemetic effect evaluation such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP )regiment or taxanes-based regiment Existing emesis within 24 hours before chemotherapy administration Symptomatic brain metastasis or suspected clinical brain metastasis Serious uncontrolled systemic illness or medical condition: congestive heart failure, unstable angina, history of documented myocardial infarction within 6 months, uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious neurological or mental abnormalities including mental disorder, epileptic dementia, which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer or other contraindication for corticosteroid therapy. Inability to take or absorb oral medicine Concurrent administration of any other investigational drug, or have been enrolled in other clinical trial with investigational drug treatment within the 30 days of start of study treatment Unsuitable for the study or other chemotherapy determined by investigator

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Xiujuan Qu, PhD. M.D.

Phone

024-83282542

qu_xiujuan@hotmail.com

First Name & Middle Initial & Last Name or Official Title & Degree

Lingyun Zhang, PhD. M.D.

Phone

024-83282312

zhangly1105@126.com

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Yunpeng Liu, PhD. M.D.

Organizational Affiliation

China Medical University, China

Official's Role

Principal Investigator

Facility Information:

Facility Name

cancer hospital of Haerbin Medical University

City

Haerbin

State/Province

Heilongjiang

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jin Wu, M.D.

Facility Name

Siping City Cancer Hospital

City

Siping

State/Province

Jilin

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Zhuohui Qu

First Name & Middle Initial & Last Name & Degree

Zhuohui Qu

Facility Name

Anshan Hospital of First Hospital of China Medical University

City

Anshan

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Mingran Sun, PhD.M.D.

First Name & Middle Initial & Last Name & Degree

Mingran Sun

Facility Name

Anshan Tumor Hospital

City

Anshan

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Xiuna Zhang, M.D.

First Name & Middle Initial & Last Name & Degree

Xiuna Zhang

First Name & Middle Initial & Last Name & Degree

Jinfang Lv

First Name & Middle Initial & Last Name & Degree

Fugang When

First Name & Middle Initial & Last Name & Degree

Li Man

Facility Name

Central hospital of Dalian

City

Dalian

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Wei Huo

First Name & Middle Initial & Last Name & Degree

Wei huo

First Name & Middle Initial & Last Name & Degree

Min Zhong

First Name & Middle Initial & Last Name & Degree

Liangwei Yin

Facility Name

Second Affiliated Hospital of Dalian Medical University

City

Dalian

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Zhaoxia Dai, M.D.

First Name & Middle Initial & Last Name & Degree

Zhaoxia Dai

First Name & Middle Initial & Last Name & Degree

Jun Chen

Facility Name

The Fifth Hospital of Dalian City

City

Dalian

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jilai Bian

First Name & Middle Initial & Last Name & Degree

Jilai Bian

Facility Name

The First Affiliated Hospital of Dalian Medical University

City

Dalian

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jiwei Liu, PhD;M.D.

First Name & Middle Initial & Last Name & Degree

Jiwei Liu

Facility Name

Zhuanghe Central Hospital

City

Dalian

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Huali Tang

First Name & Middle Initial & Last Name & Degree

Huali Tang

Facility Name

Fushun Central Hospital

City

Fushun

State/Province

Liaoning

Country

China

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Li Ning

First Name & Middle Initial & Last Name & Degree

Li Ning

Facility Name

General Hospital of Mining Bureau

City

Fushun

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yuyang Zhang

First Name & Middle Initial & Last Name & Degree

Yuyang Zhang

Facility Name

Jinzhou Central Hospital

City

Jinzhou

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Wei Wang

First Name & Middle Initial & Last Name & Degree

Wei Wang

Facility Name

The First Hospital of Liaoning Medical University

City

Jinzhou

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Zhitu Zhu

First Name & Middle Initial & Last Name & Degree

Zhitu Zhu

Facility Name

Chinese Medicine Hospital of Liaoyang county

City

Liaoyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Haifeng Liu, M.D.

First Name & Middle Initial & Last Name & Degree

Haifeng Liu

Facility Name

Liaoyang Central Hospital

City

Liaoyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jian Zhang, M.D.

First Name & Middle Initial & Last Name & Degree

Jian Zhang

Facility Name

Petrochemical General Hospital of Liaoyang city

City

Liaoyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hao Chen

First Name & Middle Initial & Last Name & Degree

Hao Chen

Facility Name

Panjin central Hospital

City

Panjin

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Junwei Zhang

First Name & Middle Initial & Last Name & Degree

Junwei Zhang

First Name & Middle Initial & Last Name & Degree

Zhichang Sun

First Name & Middle Initial & Last Name & Degree

Yu Jiang

First Name & Middle Initial & Last Name & Degree

Qinghua Gao

Facility Name

Chest Hospital of Shenyang City

City

Shengyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yinyin Li

First Name & Middle Initial & Last Name & Degree

Yinyin Li

Facility Name

Shengjing Hospital of China Medical University

City

Shenyang

State/Province

Liaoning

ZIP/Postal Code

110004

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Huawei Zou, M.D.

First Name & Middle Initial & Last Name & Degree

Huawei Zou

First Name & Middle Initial & Last Name & Degree

Rong Wu

Facility Name

General Hospital of Shenyang Military Region

City

Shenyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Zhendong Zheng

Facility Name

Liaoning Tumor Hospital & Institute

City

Shenyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yu Tang, M.D.

First Name & Middle Initial & Last Name & Degree

Yu Tang

Facility Name

The First Hospital of China Medical University

City

Shenyang

State/Province

Liaoning

Country

China

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yunpeng Liu, M.D.;Ph.D.

First Name & Middle Initial & Last Name & Degree

Yunpeng Liu

First Name & Middle Initial & Last Name & Degree

Xiujuan Qu

First Name & Middle Initial & Last Name & Degree

Lingyun Zhang

Facility Name

the People'S Hospital

City

Shenyang

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Lijie He, M.D.

First Name & Middle Initial & Last Name & Degree

Lijie He

Facility Name

Tieling city Central Hospital

City

Tieling

State/Province

Liaoning

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Huijun Zhang

First Name & Middle Initial & Last Name & Degree

Huijun Zhang

Facility Name

Central Hospital of Anshan City

City

Anshan

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Chuanchun Leng

First Name & Middle Initial & Last Name & Degree

Chuanchun Leng

Facility Name

Benxi Central Hospital

City

Benxi

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Tiejun Chen

First Name & Middle Initial & Last Name & Degree

Tiejun Chen

Facility Name

Chaoyang Central Hospital

City

Chaoyang

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Xiujie Cui

First Name & Middle Initial & Last Name & Degree

Xiujie Cui

Facility Name

Zhongshan Hospital

City

Dalian

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Xuening Ji, M.D.

First Name & Middle Initial & Last Name & Degree

Xuening Ji

First Name & Middle Initial & Last Name & Degree

Gang Wang

First Name & Middle Initial & Last Name & Degree

Tong Zhao

Facility Name

Liaohe Oilfield General Hospital

City

Panjin

Country

China

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Qiang Chen

First Name & Middle Initial & Last Name & Degree

Qiang Chen

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

We'll reach out to this number within 24 hrs